Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings plc, a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment, has announced the appointment of Panmure Gordon (UK) Limited as its Nominated Advisor and Joint Broker. The company, known for its proprietary research in the human adaptive immune system, is advancing a pipeline of innovative products targeting unmet needs in cancer through its four technology platforms. This strategic partnership is aimed at enhancing Scancell’s growth and development in the biopharmaceutical industry.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
